Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry.
Vij V, Cruz-González I, Galea R, Piayda K, Nelles D, Vogt L, Gloekler S, Fürholz M, Meier B, Räber L, O'Hara G, Arzamendi D, Agudelo V, Asmarats L, Freixa X, Flores-Umanzor E, De Backer O, Sondergaard L, Nombela-Franco L, McInerney A, Salinas P, Korsholm K, Nielsen-Kudsk JE, Afzal S, Zeus T, Operhalski F, Schmidt B, Montalescot G, Guedeney P, Iriart X, Miton N, Saw J, Gilhofer T, Fauchier L, Veliqi E, Meincke F, Petri N, Nordbeck P, Gonzalez-Ferreiro R, Bhatt DL, Laricchia A, Mangieri A, Omran H, Schrickel JW, Rodes-Cabau J, Nickenig G, Sievert H, Sedaghat A. Vij V, et al. Among authors: bhatt dl. Clin Res Cardiol. 2023 Dec;112(12):1790-1799. doi: 10.1007/s00392-023-02237-w. Epub 2023 Jun 9. Clin Res Cardiol. 2023. PMID: 37294311 Free PMC article.
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
Becher PM, Savarese G, Benson L, Dahlström U, Karlström P, Mol PGM, Metra M, Bhatt DL, Pitt B, Lund LH. Becher PM, et al. Among authors: bhatt dl. Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):343-352. doi: 10.1093/ehjcvp/pvad012. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36718512
Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
Verma S, David JP, Leiter LA, Michelsen MM, Rasmussen S, Bhatt DL. Verma S, et al. Among authors: bhatt dl. Diabetes Obes Metab. 2023 Aug;25(8):2388-2392. doi: 10.1111/dom.15081. Epub 2023 May 3. Diabetes Obes Metab. 2023. PMID: 37016488 No abstract available.
New approaches to reduce recurrent PCI: to angioplasty and beyond!
Sabouret P, Manzo-Silberman S, Alasnag M, Fysekidis M, Gulati M, Galati G, Spadafora L, Banach M, Biondi-Zoccai G, Bhatt DL. Sabouret P, et al. Among authors: bhatt dl. Eur Heart J Open. 2023 May 17;3(3):oead049. doi: 10.1093/ehjopen/oead049. eCollection 2023 May. Eur Heart J Open. 2023. PMID: 37273260 Free PMC article. Review. No abstract available.
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J. Petrie MC, et al. Among authors: bhatt dl. Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3548. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39725521
2,190 results